Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis

BACKGROUND: There is limited information about thymosin α1 (Tα1) as adjuvant immunomodulatory therapy, either used alone or combined with other treatments, in patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate the effect of adjuvant Tα1 treatment on long-term survival in...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Cheng-Lin, Mei, Jian-Dong, Jia, Yu-Long, Gan, Fan-Yi, Tang, Yu-Dong, Liu, Cheng-Wu, Zeng, Zhen, Yang, Zhen-Yu, Deng, Sen-Yi, Sun, Xing, Liu, Lun-Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631386/
https://www.ncbi.nlm.nih.gov/pubmed/34732663
http://dx.doi.org/10.1097/CM9.0000000000001819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631386/
https://www.ncbi.nlm.nih.gov/pubmed/34732663
http://dx.doi.org/10.1097/CM9.0000000000001819

Ejemplares similares